July 23, 2019 – Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment of adult patients with non-Hodgkin’s…Original Article
FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
